Inovelon® (rufinamide) Oral Suspension Formulation Launched in Spain

Inovelon® (rufinamide) Oral Suspension Formulation Launched in Spain PR Newswire HATFIELD, England, January 2, 2013 HATFIELD, England, January 2, 2013 /PRNewswire/ -- Child friendly formulation set to aid administration for the treatment of Lennox-Gastaut syndrome ®Inovelon (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in Spain. As many patients who receive the orphan drug rufinamide are children, the new formulation has been developed as a child friendly drinkable liquid to aid the administration of treatment. "As some children find tablets difficult to swallow, there is a strong need for drinkable medicines especially when treating younger LGS patients. In addition, the use of the rufinamide oral suspension allows for individual titration in smaller steps to find the optimal dose for each patient", said Dr. Juan Jose Garcia Peñas, Neuropediatrician at the Hospital Infantil Universitario Niño Jesus. "The availability of the suspension formulation of rufinamide will potentially help young patients adhere better to treatment which should help improve outcomes in the management of this severe and highly debilitating disease." LGS is a rare form of epilepsy accounting for five percent of all cases and [1]rising to approximately 10 percent of childhood epilepsy cases. The annual incidence of the condition affects about 2.8 per 10,000 births in [1]Europe.